93 results about "Gland cell" patented technology

The present invention relates to a method capable of using natural and artificial synthetic isosulfocyanate compound or its derivative to prevent and cure prostatic diseases and skin carcinoma. The internal tests show that various isosulfocyanate compounds or their derivatives can induce prostatic cell II phase drug metabolic detoxication enzyme-glutathione transferase so as to can inhibit the hyperplasia of prostate and inflammation, and can prevent and cure prostatic carcinoma and skin carcinoma.

The invention provides a reagent for diagnosing cervical cancer, which can not only detect the presence or absence of cervical cancer but can also distinguish squamous cell carcinoma and adenocarcinoma from each other, a method for screening cervical cancer by using the reagent, particularly a screening method capable high speed processing by utilizing flow cytometry.

The reagent comprises a first labeled antibody reacting with gland cells, a second labeled antibody reacting with adenocarcinoma cells and a third labeled antibody reacting with atypical cervical squamous cells, the antibodies being labeled with mutually distinguishable labels respectively. Preferably, at least one selected from the group consisting of MUC1 antibody, cytokeratin 7 antibody, and cytokeratin 18 antibody is used as the first labeled antibody, at least one selected from the group consisting of cytokeratin 8 antibody and HIK1083 antibody is used as the second labeled antibody, and at least one member selected from the group consisting of NMP179 antibody, p16^INK4A antibody, Ki-67 antibody, p53 antibody, p21 antibody, EMA antibody, CEA antibody and MIB-1 antibody is used as the third labeled antibody.

A novel classification system for breast cancer based on normal breast cell phenotypes and various expression levels of estrogen receptor (ER), androgen receptor (AR), and vitamin D receptor (VDR). The various categories of the classification system are associated with different survival rates and prognoses. The invention includes a method of classifying breast cancer comprises measuring the levels of ER, AR, and VDR in the cancerous tissue, and classifying the breast cancer into one of the above-noted categories according to expression levels. The invention includes a method of predicting the prognosis of breast cancer in a patient and a method of determining a treatment regimen for breast cancer depending on the category in which the breast cancer is classified. The invention includes a method of treating breast cancer according to the expression profile of ER, AR, and VDR detected in the cancerous tissue. Kits for detecting the same are also provided.

The invention discloses a method for preparing a rainbow trout IHN (Infectious Haematopoietic Necrosis) inactivated vaccine, which comprises the following steps: carrying out grinding, filtering and poison dipping processing on pancreas and livers of juvenile fish which is attacked, but is still alive, inoculating rainbow trout gonad (RTG) cells, carrying out blind passaging at 14 DEG C, keeping for 5 days when carrying out blind passaging on the tenth generation, and collecting cell poisonous fluid; inoculating chinook salmon embryonic (CHSE) cells, carrying out passaging at 14 DEG C, and raising the culture temperature by 1 DEG C when passaging for 5 generations each time until the culture temperature is raised to 20 DEG C; and adopting epithelioma papulosum cyprini (EPC) cells to continuously carry out passaging under the condition of 20 DEG C, passaging to the twelfth generation to obtain high-titer virus solution and carrying out inactivation to obtain the rainbow trout IHN inactivated vaccine. According to the preparation method, RTG-2, CHSE-214 and EPC cells are utilized to alternately culture rainbow trout IHN viruses at a specific environment temperature so as to obtain a high-titer IHNV (Infectious Hematopoietic Necrosis Virus) antigen and produce the inactivated vaccine; and the technical difficult problem that the high-titer IHNV antigen cannot be obtained through single cells is solved.

The invention relates to a sex development regulation and control technology for the male Chinese mitten crab, in particular to a sex reversal siRNA of the Chinese mitten crab and application of the siRNA. A nucleotide sequence of a positive-sense strand of the sex reversal siRNA of the male Chinese mitten crab is shown in SEQ ID NO.1, and a nucleotide sequence of an antisense strand is shown in SEQ ID NO.2. according to the sex reversal siRNA, an IAG gene segment of the Chinese mitten crab is screened from an androgenic gland transcriptome of the Chinese mitten crab, the total-length cDNA sequence of the segment is cloned, according to an IAG gene sequence of the Chinese mitten crab, the siRNA is designed, synthesized and guided into a body of the Chinese mitten crab in the sex differentiation period, expression of an IAG gene in an androgenic gland cell is disturbed, and sex reversal of the male crab is achieved. Compared with androgenic gland removal through surgery, a micro-injection method is adopted and has the advantages that the trauma to the body of the Chinese mitten crab is small, and the situation is avoided that due to wound infection after surgery, the Chinese mittencrab dies; the injection dose is extremely low, the immunological stress reaction of a tested animal is not easily triggered, and accordingly the success rate of sex reversal is increased.

This invention relates to the in vitro differentiation of pluripotent cells into pancreatic progenitors by i) culturing pluripotent cells in a definitive endoderm (DE) medium comprising a TGFp ligand, fibroblast growth factor ( FGF), bone morphogenetic protein (BMP), a PI3K inhibitor and optionally a GSK3 β inhibitor to produce a population of definitive endoderm cells, ii) culturing the definitive endoderm cells in a first pancreatic medium comprising an activin antagonist; FGF; retinoic acid; and a BMP inhibitor to produce a population of dorsal foregut cells; iii) culturing the dorsal foregut cells in a second pancreatic medium comprising FGF, retinoic acid, a BMP inhibitor, and a hedgehog signalling inhibitor, and; iv) culturing the endoderm cells in a third pancreatic medium comprising FGF. The progenitor cells thus produced may be further differentiated into pancreatic endocrine cells. These methods may be useful, for example, in producing pancreatic cells for therapy or disease modelling.

The present invention relates to the use of a compound of formula (1):

wherein: R1 comprises a carbonyl group and R2 is a hydrocarbyl group; optionally wherein said ring is further substituted; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in one or more of: modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; modulating calcium spikes in mammalian cells; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes by modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; treating diseases in one or more of brain, heart, and T-cells by modulating calcium spikes in mammalian cells.

The invention discloses a composition with acne removing and repairing functions, application of the composition in cosmetics, gel and a preparation method of the gel, and relates to the field of cosmetics. The composition is prepared from salicylic acid, a centella asiatica extract, a white willow extract, 4-terpineol, a chlorella extract, ergothioneine, a pine mushroom extract, a barosma betulina leaf extract and 10-hydroxydecanoic acid. Salicylic acid compounded with the chlorella extract and ergothioneine components is adopted to efficiently balance skin microorganisms; various plant extracts are natural and safe and have mild functions; the 4-terpineol, the white willow bark extract and the like in the formula have remarkable antibacterial and anti-inflammatory effects; the barosma betulina leaf extract, the 10-hydroxydecanoic acid and other extracts can inhibit sebaceous gland cell differentiation to achieve an efficient oil-control effect; and the ergothioneine, the chlorella extract and other extracts have an efficient repairing effect on skin, so that the product has efficient repairing, anti-inflammation and oil control functions, and has a remarkable acne removing effect and high safety.

The invention belongs to the technical field of medical biology, and discloses a molecular marker-LncRNA SNHG11 for auxiliary diagnosis of prostatic cancer. The LncRNA SNHG11 is highly expressed in cancer tissues of prostatic cancer, and is lowly expressed in paracancerous normal tissues; moreover, the expression level of the LncRNA SNHG11 in a prostatic cancer cell line is obviously higher than that of a normal prostate cell line; proliferation, migration and invasion of prostatic cancer cells can be obviously inhibited by knocking down the expression level of the LncRNA SNHG11 gene. Therefore, the LncRNA SNHG11 can be used as a molecular marker for auxiliary diagnosis of the prostatic cancer; by detecting the expression level of the LncRNA SNHG11 in a sample, auxiliary diagnosis can be carried out on the prostatic cancer, and a reference basis is provided for clinical doctors to diagnose the prostatic cancer.

The present invention discloses sow feed for improving the milk secretion amount and a preparation method thereof. The feed consists of the following raw materials in parts by weight: soybean cake powder 150-180, dried small shrimps 30-40, potato powder 6-8, gynura cusimbua 3-5, cured fly maggot powder 15-20, pericarpium canavaliae 3-4, mushroom residues 4-6, bone meal 3-4, tomato juice 2-3, sansevieria trifasciata 1-2, fish oil 3-5, peanut seedlings 4-6, rice bran 4-5, silkworm chrysalis powder 8-10, grape skins 2-3, ecklonia kurome okam 4-6, galactogogues 6-8 and a proper amount of water. The feed can stimulate mammary gland development with the addition of the galactogogues to reduce the prolactin inhibiting factor (PIF) secretion, further increase the pituitary prolactin (PRL) secretion, activate gland cells, promote the milk secretion and increase the sow milk secretion amount. The feed is strong in palatability, high in digestibility and rich in nutrition, and can supplement nutritional needs of sows, improve immunity of the sows and piglets and reduce piglet mortality.

The invention relates the isosulfocyanate compounds (ISOTHIOCYANATES), in other word, JC-5411 compounds, which can adjust the expression of androgen acceptor gene in cell by suppressing the expression of gene transcription factor SP1, and suppress the abnormal breeding function of prostate gland cell. With the little compound, it can suppress hamster benign hypertrophy of the prostate (BPH), which is induced by suppressed male sex hormone, and the growth of prostate gland cancer cell. The invention provides the new method of effectively preventing and treating the hypertrophy of the prostate and prostate gland cancer. The compound possesses the low side effect, steady chemical biology nature, low cost of manufacture, and broad adaptability.

The invention belongs to the technical field of bioengineering and in particular relates to a recombination method and application of a luciferase reporter gene with a human aquaporin 1 (AQP1) promoter to drug screening. The highly expressed AQP1 plays an important role in the salivary secretion process and is closely related to onset of Sjogren syndromes. In the invention, a 1868bp AQP1 promoter sequence is amplified from a personal genome by utilizing the gene engineering technology and is cloned onto a PGL2-luc vector to construct an AQP1 promoter-Luc expression vector. AQP1 expression is controlled by a promoter region. Constructing a salivary gland cell model with the AQP1 promoter is a key step for screening the traditional Chinese medicine ingredients which can treat the Sjogren syndromes. The drug screening cell model proves that ginseng and American ginseng ingredients at certain concentrations can promote transcription of the AQP1 promoter and the higher the concentrations are, the stronger the activity is, and can guide the drugs to be clinically applied to treat the Sjogren syndromes.

The invention relates to an application of deer oil in the preparation of beauty breast cosmetics, and belongs to an application of an economical animal oil in the cosmetic field. The deer oil has functions of skin moistening and breast beautification and enhancement, fundamentally repairs and activates breast gland cells, recultures breast cells, supplement necessary nutrient elements, promotes to increase breast tissues and helps corrects flat chest, microemulsion, breast collapse and depression so as to make breast plump and elastic, make skin soft, smooth and tender, and actually improve mastitis.

The invention discloses an oligopeptide with breast cancer resisting activity. A sequence of the oligopeptide is His-Asn-Tyr-Gly-Phe-Val-Pro-Ser-Leu. The oligopeptide with low concentration also can selectively suppress growth of extracorporeal breast cancer cells and does not affect growth of normal mammary gland cells. Extracorporeal tests also show that the oligopeptide has a high suppression effect for the growth and proliferation of cancer cells, and obvious dose and effect relation is displayed. Owing to the safe, efficient and ideal anti-cancer effect, the oligopeptide can be used for preparing anti-cancer medicines and has a good application prospect.

The invention discloses an oligopeptide with breast cancer resistant activity. The oligopeptide has a sequence of His-Asn-Tyr-Gly-Phe-Val-Pro-Ser-Leu. The oligopeptide can selectively inhibit the growth of in-vitro breast cancer cells under low concentration and does not have any influence on normal breast cells. In-vivo experiments show that the oligopeptide has a strong effect of inhibiting the growth and proliferation of cancer cells and has an obvious dose-effect relationship. Because of a safe, efficient and ideal anti-cancer effect, the oligopeptide can be used for preparing anti-cancer medicines and has a good application prospect.

This invention relates to the discovery that an intermediate, differentiated stage of pancreatic stem cells exist that can be matured in situ into a stable cell line that produces insulin in response to glucose. These cells are advantageous in that they are both expandable and stable in culture. This invention avoids the step of culturing the intermediate stage stem cells into later stage pancreatic cells.

The invention discloses a bombyx mori middle silkgland bioreactor universal plasmid for expressing T4 ligase as well as an application and a method of the universal plasmid. The plasmid takes a piggyBac transposon as a base and contains an Amp resistance gene, and the plasmid comprises functional expression cassettes of the T4 ligase which serves as an exogenous gene and a green fluorescent EGFP gene which is used as a marker gene; the plasmid is constructed by virtue of a molecular biological method, and two specific restriction enzyme cutting sites, namely ApaI and NheI, exist between DDDDK and a light-chain fibroin gene polyA; the double-enzyme-digestion universal plasmid of the ApaI and NheI, after linked to the T4 ligase gene, is injected into fertilized eggs of bombyx mori together with an auxiliary plasmid; on the basis of the property of the transposon, the green fluorescent protein gene and the T4 ligase gene are delivered into a bombyx mori genome and are stably inherited and expressed, so that transgenic bombyx mori is obtained. According to the universal plasmid disclosed by the invention, the transgenic bombyx mori is screened by virtue of the fluorescent marker gene, and T4 ligase protein is specifically synthesized and secreted by virtue of bombyx mori gland cells.

Herein is reported a method for producing a thymocyte supernatant comprising the steps of co-cultivating thymocytes and mononuclear cells at a cell ratio of at least 0.5:1.2 in the presence of phorbol-12-myristate-13-acetate and Phytohemagglutinin M for up to 60 hours, and separating the co-cultivation medium from the cells and thereby producing the thymocyte supernatant.

The invention discloses a pharmaceutical composition (a formula capable of strengthening body resistance and removing stasis) for treating hashimoto thyroiditis and a preparation method thereof. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 10 to 20 parts of radix ginseng, 30 to 45 parts of radix astragali seu hedysari, 20 to 30 parts of radix et rhizoma salviae miltiorrhizae, 15 to 25 parts of liquorice root, 15 to 25 parts of white paeony root, 5 to 10 parts of dried tangerine peel and 5 to 10 parts of dried ginger. The pharmaceutical composition is prepared from raw materials which are both used as medicines and foods or can be used for health-care products, has no toxic side effect and has low cost. A drug effect test proves that the traditional Chinese medicine composition provided by the invention can be used for effectively repairing shapes of thyroid gland cells, reducing lymphocytes infiltration, remarkably reducing a thyroid autoantibody and a thyroid hormone level, reducing TNF-alpha (Tumor Necrosis Factor-alpha) and raising IL-10 and has a remarkable treatment effect on the hashimoto thyroiditis.